{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-041102","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.152802+00:00","generated_at":"2026-05-31T04:33:47.798027+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PDS Biotech reports updated VERSATILE-002 trial data: mOS 30 months, ORR 36%","bullets":["Median overall survival 30 months vs published 12-18 months for pembrolizumab alone.","Objective response rate 36% (19/53); disease control rate 77% (41/53).","21% of patients (11/53) had 90-100% tumor shrinkage; 9% (5/53) complete response.","Phase 3 VERSATILE-003 trial comparing combo vs pembrolizumab monotherapy planned to start in 2024.","Treatment well tolerated; Grade ≥3 AEs in 9 patients (Grade 3 n=8, Grade 4 n=1)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-041102","json":"https://secwatch.observer/filing/0001140361-24-041102.json","markdown":"https://secwatch.observer/filing/0001140361-24-041102.md","text":"https://secwatch.observer/filing/0001140361-24-041102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124041102/0001140361-24-041102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124041102/ef20035887_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:33:47.798027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}